Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Designer antiandrogens join the race against drug resistance.

eLife - 9 Apr 2013

Josan Jatinder S, Katzenellenbogen John A

Abstract excerpt

By using in silico models of the complexes formed by analogues of a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Drug Design
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 23580166
DOI: 10.7554/eLife.00692
PMCID: PMC3622176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Designer antiandrogens join the race against drug resistance.PMID 23580166Read ↗

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read ↗

Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.Semantic proximity Read ↗

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancerSemantic proximity Read ↗

Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.Semantic proximity Read ↗

Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.Semantic proximity Read ↗

Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations.Semantic proximity Read ↗

Molecular dynamics simulations reveal the plausible agonism/antagonism mechanism by steroids on androgen receptor mutations.Semantic proximity Read ↗

Computational design, synthesis, and evaluation of miniproteins as androgen receptor coactivator mimics.Semantic proximity Read ↗

In Silico Evaluation of the Binding Energies of Androgen Receptor Agonists in Wild-Type and Mutational Models.Semantic proximity Read ↗

FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.